IL157815A0 - Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain - Google Patents
Fused pyridine derivatives for use as vanilloid receptor antagonists for treating painInfo
- Publication number
- IL157815A0 IL157815A0 IL15781502A IL15781502A IL157815A0 IL 157815 A0 IL157815 A0 IL 157815A0 IL 15781502 A IL15781502 A IL 15781502A IL 15781502 A IL15781502 A IL 15781502A IL 157815 A0 IL157815 A0 IL 157815A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- treating pain
- pyridine derivatives
- vanilloid receptor
- fused pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0107505A GB0107505D0 (en) | 2001-03-26 | 2001-03-26 | Organic compounds |
US33828101P | 2001-12-06 | 2001-12-06 | |
PCT/EP2002/003332 WO2002076946A2 (en) | 2001-03-26 | 2002-03-25 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. |
Publications (1)
Publication Number | Publication Date |
---|---|
IL157815A0 true IL157815A0 (en) | 2004-03-28 |
Family
ID=26245894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15781502A IL157815A0 (en) | 2001-03-26 | 2002-03-25 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
Country Status (17)
Country | Link |
---|---|
US (1) | US7915264B2 (xx) |
EP (1) | EP1377576A2 (xx) |
JP (1) | JP4205430B2 (xx) |
KR (1) | KR20030083755A (xx) |
CN (1) | CN1500089A (xx) |
BR (1) | BR0208338A (xx) |
CA (1) | CA2441599A1 (xx) |
CZ (1) | CZ20032561A3 (xx) |
HU (1) | HUP0303623A2 (xx) |
IL (1) | IL157815A0 (xx) |
MX (1) | MXPA03008754A (xx) |
NO (1) | NO326546B1 (xx) |
PE (1) | PE20021161A1 (xx) |
PL (1) | PL363907A1 (xx) |
RU (1) | RU2003130221A (xx) |
SK (1) | SK11952003A3 (xx) |
WO (1) | WO2002076946A2 (xx) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004506714A (ja) | 2000-08-21 | 2004-03-04 | パシフィック コーポレーション | 新規チオ尿素化合物及びこれを含有する薬学的組成物 |
ATE393141T1 (de) | 2000-08-21 | 2008-05-15 | Pacific Corp | Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten |
KR20040085151A (ko) | 2002-01-17 | 2004-10-07 | 뉴로젠 코포레이션 | 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체 |
JP4583760B2 (ja) | 2002-02-01 | 2010-11-17 | ユーロ−セルティーク エス.エイ. | 疼痛の治療に有用な治療薬 |
US6864261B2 (en) | 2002-05-02 | 2005-03-08 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
GB0229808D0 (en) * | 2002-12-20 | 2003-01-29 | Glaxo Group Ltd | Novel compositions |
ATE450533T1 (de) * | 2003-02-14 | 2009-12-15 | Glaxo Group Ltd | Carboxamidderivate |
ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
GB0319150D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
US20070135454A1 (en) | 2003-11-14 | 2007-06-14 | Tracy Bayliss | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
WO2006019965A2 (en) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2008508190A (ja) | 2004-07-19 | 2008-03-21 | ノボ ノルディスク アクティーゼルスカブ | 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害 |
DE102004039373A1 (de) | 2004-08-12 | 2006-02-23 | Grünenthal GmbH | Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln |
KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
WO2006098554A1 (en) * | 2005-03-16 | 2006-09-21 | Amorepacific Corporation | Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same |
GB0506147D0 (en) * | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
US20090298856A1 (en) * | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
AU2006303437B2 (en) * | 2005-10-19 | 2012-06-28 | Grunenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
KR100761222B1 (ko) * | 2006-03-08 | 2007-10-04 | 성균관대학교산학협력단 | 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제 |
GB0614471D0 (en) | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
ES2399928T3 (es) | 2006-08-23 | 2013-04-04 | Neurogen Corporation | Análogos de 2-fenoxipirimidinona |
EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
WO2008129000A1 (en) * | 2007-04-20 | 2008-10-30 | Novartis Ag | Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders |
CN101754774B (zh) | 2007-07-18 | 2013-08-21 | 诺瓦提斯公司 | Vr-1拮抗剂和cox-2抑制剂的协同组合 |
US8349846B2 (en) * | 2008-01-11 | 2013-01-08 | Glenmark Pharmaceuticals, S.A. | Fused pyrimidine derivatives as TRPV3 modulators |
WO2009121036A2 (en) * | 2008-03-27 | 2009-10-01 | Neurogen Corporation | Substituted aryl pyrimidinone derivatives |
ES2539290T3 (es) | 2008-04-18 | 2015-06-29 | Daewoong Pharmaceutical Co., Ltd. | Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
CN107108429B (zh) * | 2015-12-23 | 2022-08-19 | 联邦科学与工业研究组织 | 化合物 |
CN108863949B (zh) * | 2018-07-09 | 2021-01-15 | 湖南博隽生物医药有限公司 | 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法 |
DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2749344A (en) * | 1953-01-02 | 1956-06-05 | Burroughs Wellcome Co | Pyrimidine compounds |
US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
US5620978A (en) | 1994-01-03 | 1997-04-15 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor |
FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
-
2002
- 2002-03-25 KR KR10-2003-7012460A patent/KR20030083755A/ko not_active Application Discontinuation
- 2002-03-25 PL PL02363907A patent/PL363907A1/xx not_active Application Discontinuation
- 2002-03-25 CZ CZ20032561A patent/CZ20032561A3/cs unknown
- 2002-03-25 CN CNA028073495A patent/CN1500089A/zh active Pending
- 2002-03-25 SK SK1195-2003A patent/SK11952003A3/sk unknown
- 2002-03-25 EP EP02730062A patent/EP1377576A2/en not_active Withdrawn
- 2002-03-25 IL IL15781502A patent/IL157815A0/xx unknown
- 2002-03-25 JP JP2002576207A patent/JP4205430B2/ja not_active Expired - Fee Related
- 2002-03-25 MX MXPA03008754A patent/MXPA03008754A/es not_active Application Discontinuation
- 2002-03-25 BR BR0208338-8A patent/BR0208338A/pt not_active IP Right Cessation
- 2002-03-25 RU RU2003130221/04A patent/RU2003130221A/ru not_active Application Discontinuation
- 2002-03-25 CA CA002441599A patent/CA2441599A1/en not_active Abandoned
- 2002-03-25 US US10/469,756 patent/US7915264B2/en not_active Expired - Fee Related
- 2002-03-25 HU HU0303623A patent/HUP0303623A2/hu unknown
- 2002-03-25 WO PCT/EP2002/003332 patent/WO2002076946A2/en not_active Application Discontinuation
- 2002-03-26 PE PE2002000241A patent/PE20021161A1/es not_active Application Discontinuation
-
2003
- 2003-09-16 NO NO20034122A patent/NO326546B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP4205430B2 (ja) | 2009-01-07 |
SK11952003A3 (sk) | 2004-03-02 |
HUP0303623A2 (hu) | 2004-03-01 |
CA2441599A1 (en) | 2002-10-03 |
PE20021161A1 (es) | 2003-02-21 |
BR0208338A (pt) | 2004-03-09 |
NO20034122D0 (no) | 2003-09-16 |
CZ20032561A3 (cs) | 2003-12-17 |
WO2002076946A3 (en) | 2002-12-27 |
US7915264B2 (en) | 2011-03-29 |
JP2004528312A (ja) | 2004-09-16 |
RU2003130221A (ru) | 2005-04-10 |
KR20030083755A (ko) | 2003-10-30 |
CN1500089A (zh) | 2004-05-26 |
US20040138454A1 (en) | 2004-07-15 |
NO20034122L (no) | 2003-09-16 |
MXPA03008754A (es) | 2004-02-18 |
PL363907A1 (en) | 2004-11-29 |
NO326546B1 (no) | 2009-01-05 |
WO2002076946A2 (en) | 2002-10-03 |
EP1377576A2 (en) | 2004-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157815A0 (en) | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | |
HK1066534A1 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
HUP0301671A3 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use | |
HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
HK1047580B (zh) | 在糖尿病治療中作為糖皮質激素受體對抗劑的二苯並吡喃 | |
IL159350A0 (en) | Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury | |
HK1081182A1 (en) | Substituted piperidine compounds for use as h3 histamine receptor antagonists | |
HK1044942A1 (en) | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists | |
MXPA03009644A (es) | Grupos azabiciclicos sustituidos para el tratamiento de enfermedades. | |
IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
AU2002352476A8 (en) | Urea derivatives and their use as vanilloid receptor antagonists | |
PL356990A1 (en) | Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists | |
HUP0202253A3 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
AU2003290059A8 (en) | Use of cd137 antagonists for the treatment of tumors | |
EP1248607A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
EP1359915A4 (en) | UROTENSIN-II RECEPTOR ANTAGONISTS | |
HUP0100934A3 (en) | Use of fused pyridine derivatives for production pharmaceutical compositions for the treatment of depression, anxiety or psychopathy | |
PL350536A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor | |
AU2003264297A1 (en) | Use of vanilloid receptor antagonists for the treatment of pain | |
IL156087A0 (en) | Histamine receptor antagonists | |
EP1377289A4 (en) | HETEROCYCLIC COMPOUNDS WITH THERAPEUTIC USE | |
SI1200402T1 (sl) | Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj | |
PL376605A1 (pl) | Zastosowanie peptydów o działaniu antagonistycznym wobec bradykininy | |
AU2003245995A8 (en) | Use of gaba-c receptor antagonists for the treatment of myopia |